Dr. Lens is presently affiliated with the Genetic Epidemiology Division, Cancer Research UK, St. James’ University Hospital, Leeds, England.
Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease
Version of Record online: 11 JAN 2006
Volume 19, Issue 1, pages 9–18, January 2006
How to Cite
Lens, M. (2006), Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease. Dermatologic Therapy, 19: 9–18. doi: 10.1111/j.1529-8019.2005.00051.x
- Issue online: 11 JAN 2006
- Version of Record online: 11 JAN 2006
- adjuvant therapy;
- high-risk melanoma;
- melanoma therapy
ABSTRACT: Systemic adjuvant therapy in melanoma patients is the systemic treatment that is administered with the goal of eradicating micrometastatic deposits in patients who are clinically free of disease after surgical removal of the primary melanoma, but with a high risk of systemic recurrence. Interferon-alpha (IFN-α) is one of the most frequently used adjuvant therapies. Several randomized trials evaluated the efficacy of IFN-α in melanoma patients. However, results from conducted trials are controversial. Twelve randomized IFN-α trials are discussed in detail. All trials, including meta-analysis, failed to demonstrate a clear impact of IFN-α therapy on overall survival in melanoma patients. Based on currently available evidence, IFN-α therapy in the adjuvant setting should not be considered standard of care for patients who have melanoma. Results from ongoing studies are awaited. Further research for this therapy is required.